Pharma major mulls over sale of Consumer Health unit

5 September 2017

Shares in German life sciences company Merck KGaA (MRK:DE) had climbed by more than 3% to 95.10 euros ($113) by lunchtime on Tuesday after the firm announced it was preparing strategic options for its Consumer Health business.

Options being considered include a potential full or partial sale of the business, as well as strategic partnerships. The unit achieved sales of 860 million euros in 2016 and boasts some well-known brands such as the nutritional supplements Seven Seas and the decongestant Nasivin.

But sales have lagged behind other units and Merck has been forced to review its strategy and consider how to ensure its financial targets are met, partly due to a decline in its liquid crystal business.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK